Oxford Vacmedix UK Limited

Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Oxford Vacmedix is looking for large pharmaceutical companies interested in co-developing the ROP technology, NHS hospitals to participate in clinical trials of the lead vaccines, and firms that can sequence tumour mutations against which it can design personalised vaccines (neoantigens). Oxford Vacmedix is looking for a large pharmaceutical firm to codevelop its ROP technology, a suitable CMO for GMP-level production for its preclinical/phase 1 vaccine trials in Europe.